Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy

We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as firs-tline chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population. We analyzed 54 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Hye-Suk, Kim, Jin-Soo, Park, Jin Hyun, Jeon, Yoon Kyung, Lee, Keun-Wook, Oh, Do-Youn, Kim, Jee Hyun, Park, So Yeon, Im, Seock-Ah, Kim, Tae-You, Park, In Ae, Bang, Yung-Jue
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752777/
https://www.ncbi.nlm.nih.gov/pubmed/19794992
http://dx.doi.org/10.3346/jkms.2009.24.5.910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752777/
https://www.ncbi.nlm.nih.gov/pubmed/19794992
http://dx.doi.org/10.3346/jkms.2009.24.5.910

Ejemplares similares